Spago Nanomedical AB (publ) (STO:SPAGO)

Market Cap	85.67M
Revenue (ttm)	5.84M
Net Income (ttm)	-28.49M
Shares Out	661.57M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,500
Average Volume	377,204
Open	0.1290
Previous Close	0.1295
Day's Range	0.1255 - 0.1290
52-Week Range	0.0842 - 0.4600
Beta	1.31
RSI	58.55
Earnings Date	Feb 2, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPAGO

Financial Performance

In 2024, Spago Nanomedical AB's revenue was 6.65 million, an increase of 17.94% compared to the previous year's 5.64 million. Losses were -32.51 million, -23.01% less than in 2023.